Experienced in Primary Biliary Cholangitis

Yida L. Yang

State Key Laboratory For Diagnosis And Treatment Of Infectious Diseases, 
Hangzhou, CN 
Experienced in Primary Biliary Cholangitis
State Key Laboratory For Diagnosis And Treatment Of Infectious Diseases, 
Hangzhou, CN 
OverviewLocationsClinical Research

Overview

Yida Yang practices in Hangzhou, China. Yang is rated as an Experienced expert by MediFind in the treatment of Primary Biliary Cholangitis. Their top areas of expertise are Gastrointestinal Bleeding, Cirrhosis, Hepatitis B, and Hepatitis.

Their clinical research consists of co-authoring 48 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Primary Biliary Cholangitis.

Locations

State Key Laboratory For Diagnosis And Treatment Of Infectious Diseases, Hangzhou, 310024, China
Other Locations
Shanghai, 200120, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy
A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy
Enrollment Status: Completed
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drug: PegIFN alfa-2a
Study Phase: Phase 4
A Real-world Clinical Study on Effectiveness and Safety of Long-term TAF Treatment in Chronic Hepatitis B Patients in China
A Real-world Clinical Study on Effectiveness and Safety of Long-term TAF Treatment in Chronic Hepatitis B Patients in China
Enrollment Status: Unknown
Publish Date: November 26, 2019
Intervention Type: Drug
View 1 Less Clinical Trial

48 Total Publications

Pre-Existing Th1 Immunity Outperforms Age in Predicting Antibody Responses to SARS-CoV-2 Inactivated Vaccines.
Pre-Existing Th1 Immunity Outperforms Age in Predicting Antibody Responses to SARS-CoV-2 Inactivated Vaccines.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: July 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yang's expertise for a condition
ConditionClose
        View All 14 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile